

# EVOTEC AG

ISIN: DE0005664809 WKN: 566480 Asset Class: Stock

<b>Company</b>	2023/09/22 12:58:40
	<b>Price</b> <b>19.62</b> EUR
	<b>Difference</b> <span style="color: green;">↑</span> 1.82%(0.35)



Contact Details	
EVOTEC SE	Tel: +49-40-56081-0
--	Fax: +49-40-56081-222
Manfred Eigen Campus, Essener Bogen 7	Web: <a href="http://evotec.com">http://evotec.com</a>
22419 Hamburg	E-mail: <a href="mailto:info@evotec.com">info@evotec.com</a>

## Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	1,073,671,000		1,100,940,000		658,844,000	
<b>Common stock capital</b>		176,953,000		176,608,000		163,915,000
<b>Fixed assets</b>	1,232,464,000		1,175,323,000		843,633,000	
<b>Equity capital of a company</b>		1,187,184,000		1,377,685,000		722,846,000
<b>Cash and cash equivalents</b>	415,155,000		699,326,000		422,580,000	
<b>Accrued liabilities</b>		16,427,000		18,021,000		22,899,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		337,706,000		324,516,000		208,459,000
<b>Prepayments and accrued income</b>		-		-		-
<b>Non-current liabilities</b>		781,245,000		574,062,000		571,172,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		207,113,000		34,943,000		26,335,000
<b>Total assets</b>	2,306,135,000	2,306,135,000	2,276,263,000	2,276,263,000	1,502,477,000	1,502,477,000

## Balance notes

	2022	2021	2020
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	4,952	4,198	3,572
<b>Equity ratio</b>	51.48%	60.52%	48.11%
<b>Debt-equity ratio</b>	94.25%	65.22%	107.86%

## Others

	2022	2021	2020
<b>Tax Expense Rate</b>	11.72%	-4.75%	-52.04%

## Income statement

	2022	2021	2020
<b>Turnover</b>	751,448,000	618,034,000	500,924,000
<b>Net income</b>	-175,655,000	215,510,000	6,252,000
<b>EBIT</b>	-176,079,000	228,532,000	18,101,000
<b>Operating income before taxes</b>	-180,893,000	221,550,000	10,975,000
<b>Cash Flow</b>	203,106,000	122,237,000	44,721,000
<b>Net interest income</b>	-4,814,000	-6,982,000	-7,126,000
<b>Research and development expenses</b>	76,642,000	72,200,000	63,945,000
<b>Income taxes</b>	-21,202,000	-10,530,000	-5,711,000
<b>Result from investments in subsidiaries, associates and other</b>	-15,964,000	-16,570,000	-10,434,000
<b>Revenues per employee</b>	151,746	147,221	140,236

## Board of Directors

Iris Löw-Friedrich	Chairman of Supervisory Board
Constanze Ulmer-Eilfort	Member of Supervisory Board
Elaine Sullivan	Member of Supervisory Board
Mario Polywka	Member of Supervisory Board
Camilla Languille	Member of Supervisory Board
Roland Sackers	Member of Supervisory Board

## Members of Management Board

Werner Lanthaler	Chairman of Managing Board
Cord Dohrmann	Member of Executive Committee
Craig Johnstone	Member of Executive Committee
Matthias Evers	Member of Executive Committee
Laetitia Rouxel	Member of Executive Committee
Volker Braun	Member of Executive Committee